While legislation and lawsuits sought to blunt PAMA's impact, labs also employed new technologies and strategies to cope with anticipated price cuts.
The bill, which will delay reporting of lab payment data required by PAMA, will now be passed on to the President, who is expected to sign it into law.
Efforts to pass a nationwide surprise billing law appear stalled for now, but state laws and proposals for federal legislation still loom large for labs.
These developments indicate that the law, which would delay the reporting of lab payment data required by PAMA, stands a good chance of passing in 2019.
The company's newest products and planned updates reveal a focus on operational efficiency and increasing automation for core lab management.
Tempus said that Akesogen's lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and more.
While pass-through billing has long been a regular part of the lab landscape, some newer arrangements run afoul of payor policies and anti-kickback laws.
The company intends to use the net proceeds to repay at maturity or redeem its $800 million aggregate principal amount of senior notes due in 2020.
While the Lab 2.0 vision is still in its early days, a number of outfits around the country are providing examples of how it might be implemented.
Though the pace of Quest's acquisitions has slowed this year, the latest deal with BCL continues a string of activities resulting from the implementation of PAMA.
In the long term, the company is developing a plan to create more tests based on its technology, which digitizes blood samples and turns them into images.
The firm is offering total consideration of $1,018.36 per $1,000 for notes tendered by Dec. 2, which includes an early tender premium of $30 per $1,000.
The US DOJ had alleged Boston Heart Diagnostics conspired to pay doctors kickbacks that were disguised as investment returns.
Microbiology lab and industry stakeholders are increasingly working together to coordinate approaches and generate more clinical utility data for diagnostic testing.
The owner is accused of falsely billing Medicare for cancer genomic testing and pharmacogenetic testing that regularly exceeded $12,000 per beneficiary.
The offering consists of two tranches, $400 million of 2.3 percent senior notes due 2024 and $650 million of 2.95 percent senior notes due 2029.
The firm said that it will use proceeds from the sale to purchase or repay other notes or loans, including up to $300 million in outstanding senior notes.
The test will now be considered medically reasonable and necessary for patients over 45 with moderately elevated levels of prostate-specific antigen.
Comments from Quest suggest lab buys are becoming more complex while others suggest hospitals will remain reluctant to sell so long as premium pricing persists.
This report contains a quantitative, evidence-based scoring framework to help guide the evaluation of constitutional CNVs across clinical labs.